HC Wainwright Lowers Genmab A/S (NASDAQ:GMAB) Price Target to $38.00
by Doug Wharley · The Cerbat GemGenmab A/S (NASDAQ:GMAB – Get Free Report) had its price target reduced by research analysts at HC Wainwright from $40.00 to $38.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 43.67% from the company’s previous close.
A number of other analysts also recently weighed in on the stock. Guggenheim reduced their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Wolfe Research initiated coverage on shares of Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Jefferies Financial Group assumed coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 price target on the stock. Finally, Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.07.
Check Out Our Latest Stock Report on GMAB
Genmab A/S Stock Down 0.3%
Shares of Genmab A/S stock opened at $26.45 on Thursday. The business has a fifty day simple moving average of $27.43 and a 200 day simple moving average of $30.06. The stock has a market cap of $16.99 billion, a PE ratio of 17.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.86. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. Genmab A/S has a 12 month low of $18.89 and a 12 month high of $35.43.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Research analysts predict that Genmab A/S will post 1.18 EPS for the current year.
Institutional Trading of Genmab A/S
A number of large investors have recently bought and sold shares of GMAB. Diversify Wealth Management LLC bought a new position in Genmab A/S in the first quarter valued at approximately $1,216,000. Kestra Advisory Services LLC increased its position in shares of Genmab A/S by 218.8% during the first quarter. Kestra Advisory Services LLC now owns 9,988 shares of the company’s stock worth $268,000 after acquiring an additional 6,855 shares in the last quarter. Personal CFO Solutions LLC increased its position in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock worth $292,000 after acquiring an additional 386 shares in the last quarter. Integrated Advisors Network LLC acquired a new stake in shares of Genmab A/S during the first quarter worth $205,000. Finally, AdvisorShares Investments LLC lifted its position in Genmab A/S by 2.2% in the 1st quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company’s stock valued at $828,000 after acquiring an additional 653 shares in the last quarter. 7.07% of the stock is owned by institutional investors.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.
Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.